Head-to-head evidence
retatrutide vs UBT251
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
retatrutide
Developed by Eli Lilly
NCT04881760 · Phase 2 · completed
The trial randomized 338 participants to double-blinded weekly LY3437943 or matched placebo. Its primary clinical endpoint, mean percent change in body weight at Week 24, was significantly favorable for every LY3437943 dose compared with placebo (all p<0.001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
UBT251
Developed by Novo Nordisk under a licence from United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07395687 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: retatrutide's landscape · UBT251's landscape